Developer docs
API playgroundTry for free, no card

Search company profiles

Quest PharmaTech

Full company profile

uuid0006xm1

Namestring
Quest PharmaTech
Legal namestring
Quest PharmaTech Inc.
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Quest PharmaTech Inc. is a Canadian clinical-stage pharmaceutical company publicly traded on the TSX Venture Exchange (QPT:TSXV) and headquartered in Edmonton, Alberta. The company is developing Mab AR 9.6, a humanized monoclonal antibody that targets truncated O-glycan on MUC16 (the CA125 tumor marker) and blocks oncogenic signaling through the EGF receptor and alpha-4-beta integrin pathways. The platform underpins multiple product candidates spanning therapeutic antibodies for pancreatic and ovarian cancer, a near-infrared fluorescence conjugate for intraoperative imaging, an immunoPET diagnostic agent, and a radioimmunotherapy program.

The company operates a hybrid asset-development and investment-holding model. Quest owns approximately 26.6% of Korean private biotech OQPBIOM (valued at $19.8 million), a 10.67% direct interest plus 12% indirect interest in OncoVent, and exposure to OncoQuest, with OncoQuest's immunotherapy assets having been transferred to OQPBIOM. Total assets stood at $27.8 million for the fiscal year ended January 31, 2026, with 1-10 employees and no commercialized products or disclosed revenue. Leadership includes CEO Dr. Madi Madiyalakan (since August 2006) and Chairman J. Mark Lievonen (former President of Sanofi Pasteur Limited, 1999-2016).

Quest has no recurring revenue and functions as a publicly listed vehicle for clinical-stage antibody development and strategic biotech investments. Its near-term economics are driven primarily by the value trajectory of OQPBIOM rather than by internal product commercialization. Recent clinical setbacks include a Phase III Oregovomab futility failure, and the company has publicly opposed OQPBIOM's proposed acquisition of South Korea-based AdBioTech, reflecting active shareholder-level governance intervention in the investee portfolio.

Short descriptiontext

Quest PharmaTech Inc. is a TSX-V listed Canadian clinical-stage pharmaceutical company developing the Mab AR 9.6 humanized monoclonal antibody targeting MUC16 for pancreatic and ovarian cancer therapy, imaging, and radioimmunotherapy applications, operating alongside equity stakes in Korean biotech OQPBIOM and OncoVent.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapy, cancer immunotherapy, targeted oncology therapeutics, radioimmunotherapy agents, theranostic imaging
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Immunotherapy
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quest PharmaTech is a Canadian pharmaceutical company developing antibody-based immunotherapeutic products for cancer centered on its lead candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated O-glycan on MUC16. The product pipeline includes targeted therapy for pancreatic and ovarian cancers, a near-infrared fluorescence antibody conjugate for fluorescence-guided surgery, a radio-labeled immunoPET imaging agent, and a radioimmunotherapy approach for MUC16-expressing tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Structural characterization of Mab AR 9.6 in complex with MUC16 revealed non-linear epitope influenced by glycosylation
+1 more record
Product overview1 text field

Quest PharmaTech is a Canadian pharmaceutical company developing a portfolio of cancer therapeutics and diagnostics centered around its lead product candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated MUC16. The company's product pipeline includes therapeutic applications for pancreatic cancer, fluorescence-guided surgical imaging agents, immunoPET imaging agents, and radioimmunotherapy. The company also maintains strategic investments in biotechnology companies including OQPBIOM (26.6% ownership, Korean immunotherapy developer) and OncoVent (10.67% direct + 12% indirect ownership).

Product and service4 records
1Mab AR 9.6
CategoryCancer immunotherapy / oncology biologics
Description

A humanized monoclonal antibody targeting truncated O-glycan on MUC16 for targeted cancer therapy applications, including pancreatic cancer and ovarian cancer treatment. The antibody blocks oncogenic activities and tumor growth by interfering with EGF receptor and alpha-4-beta-integrin signaling pathways. Intended for biopharmaceutical licensing partners and ultimately for oncology patients with MUC16-expressing tumors.

2Fluorescence Antibody Conjugate for Intraoperative Imaging
CategoryCancer diagnostics / surgical imaging agents
Description

A near-infrared fluorescent antibody conjugate derived from Mab AR 9.6 for fluorescence-guided intraoperative imaging of pancreatic cancer. Enables surgeons to visualize MUC16-expressing tumor tissue during surgery, targeting improved surgical outcomes for oncology patients.

3ImmunoPET Imaging Agent
CategoryCancer diagnostics / molecular imaging
Description

A radio-labeled immunoPET imaging agent based on Mab AR 9.6 for non-invasive imaging of ovarian and pancreatic cancer. Provides diagnostic imaging capability using a MUC16-targeted tracer for oncology clinicians and imaging centers.

4Radioimmunotherapy (Mab AR 9.6-based)
CategoryCancer radioimmunotherapy
Description

A radioimmunotherapy product candidate using Mab AR 9.6 for the treatment of cancers expressing MUC16, intended as a therapeutic option for patients with MUC16-positive tumors. Developed for oncology biopharmaceutical licensing partners and ultimately oncology patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2025-06-10
Description

AdBioTech is a South Korea-based company proposed to be acquired by OQPBIOM. Quest PharmaTech, as the largest shareholder of OQPBIOM, has publicly opposed this acquisition citing it is not in the best interest of OQM or its shareholders and is evaluating legal options.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Quest PharmaTech holds 26.6% equity interest in OQPBIOM Inc., a Korean private biotechnology company developing immunotherapy assets. OncoQuest transferred its immunotherapy assets to OQPBIOM through a series of transactions. Quest is the largest shareholder and has expressed opposition to OQPBIOM's proposed acquisition of AdBioTech.

3OncoVent
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Quest holds 10.67% direct ownership interest in OncoVent plus 12% indirect interest through its ownership in OncoQuest. OncoQuest owns 29% of OncoVent. OncoVent is linked as a partner company on Quest's website.

questpharmatech.com
4OncoQuest
Strategic tierCoreTypeStrategic or Co-development Partner
Description

OncoQuest transferred immunotherapy assets to OQPBIOM. Quest maintains an ownership position in OncoQuest as part of its investment structure. OncoQuest Pharma USA Inc. is a Delaware-incorporated subsidiary.

questpharmatech.com
Strategic tierMinorTypeOthers
Description

Canariabio is listed as a linked partner company on Quest PharmaTech's website. Nature of relationship is not explicitly detailed.

6OncoQuest Pharma USA Inc.
Strategic tierCoreTypeOthers
Description

Delaware-incorporated company and subsidiary of OncoQuest. Filed Form D notice for $360,000 USD exempt securities offering in the United States.

sec.gov
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Antibody-drug conjugate developer focused on oncology, including ovarian cancer. Directly comparable to Quest in developing antibody-based targeted cancer therapeutics leveraging tumor antigens.

TypeBroad incumbent
Description

Global pharmaceutical leader in antibody-drug conjugates (DXd platform). Comparable as a developer of antibody-conjugate oncology therapeutics, though operating at vastly greater scale and breadth.

TypeDirect peer
Description

Canadian clinical-stage immunotherapy company developing antibody-based oncology therapeutics. Closely comparable as a small Canadian biotech pursuing novel cancer biologics with similar scale and stage.

TypeRegional player
Description

Canadian clinical-stage biopharmaceutical company developing immunotherapies for cancer. Comparable as a small Canadian oncology biotech with similar jurisdictional and capital-market profile.

TypeBroad incumbent
Description

Global pharmaceutical company with significant ovarian cancer franchise (including anti-MUC16 initiatives). Comparable as a developer of MUC16-targeted and ovarian cancer therapies, though at vastly greater scale.

TypeBroad incumbent
Description

Established oncology antibody-conjugate company (now part of Pfizer). Comparable as a developer of antibody-based targeted cancer therapeutics and antibody-drug conjugates, though at much greater scale.

TypeEmerging player
Description

Clinical-stage oncology developer using Probody platform to engineer antibody-based therapeutics with tumor-selective activity. Comparable in developing engineered monoclonal antibody approaches for cancer therapy.

TypeRegional player
Description

Canadian clinical-stage biotech developing immuno-oncology therapeutics (pelareorep). Comparable as a small Canadian oncology immunotherapy developer with similar jurisdictional profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. Directly comparable in focusing on engineered monoclonal antibodies and antibody-drug conjugates for oncology indications.

TypeDirect peer
Description

Canadian clinical-stage biotech developing immunotherapy for cancer (notably breast cancer). Comparable as a small Canadian oncology immunotherapy developer with similar development-stage positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quest PharmaTech

Cancer Immunotherapyquestpharmatech.com

Quest PharmaTech Inc. is a TSX-V listed Canadian clinical-stage pharmaceutical company developing the Mab AR 9.6 humanized monoclonal antibody targeting MUC16 for pancreatic and ovarian cancer therapy, imaging, and radioimmunotherapy applications, operating alongside equity stakes in Korean biotech OQPBIOM and OncoVent.

What Quest PharmaTech does

Quest PharmaTech Inc. is a Canadian clinical-stage pharmaceutical company publicly traded on the TSX Venture Exchange (QPT:TSXV) and headquartered in Edmonton, Alberta. The company is developing Mab AR 9.6, a humanized monoclonal antibody that targets truncated O-glycan on MUC16 (the CA125 tumor marker) and blocks oncogenic signaling through the EGF receptor and alpha-4-beta integrin pathways. The platform underpins multiple product candidates spanning therapeutic antibodies for pancreatic and ovarian cancer, a near-infrared fluorescence conjugate for intraoperative imaging, an immunoPET diagnostic agent, and a radioimmunotherapy program.

The company operates a hybrid asset-development and investment-holding model. Quest owns approximately 26.6% of Korean private biotech OQPBIOM (valued at $19.8 million), a 10.67% direct interest plus 12% indirect interest in OncoVent, and exposure to OncoQuest, with OncoQuest's immunotherapy assets having been transferred to OQPBIOM. Total assets stood at $27.8 million for the fiscal year ended January 31, 2026, with 1-10 employees and no commercialized products or disclosed revenue. Leadership includes CEO Dr. Madi Madiyalakan (since August 2006) and Chairman J. Mark Lievonen (former President of Sanofi Pasteur Limited, 1999-2016).

Quest has no recurring revenue and functions as a publicly listed vehicle for clinical-stage antibody development and strategic biotech investments. Its near-term economics are driven primarily by the value trajectory of OQPBIOM rather than by internal product commercialization. Recent clinical setbacks include a Phase III Oregovomab futility failure, and the company has publicly opposed OQPBIOM's proposed acquisition of South Korea-based AdBioTech, reflecting active shareholder-level governance intervention in the investee portfolio.

Quest PharmaTech firmographics

Firmographics
Name
Quest PharmaTech
Legal name
Quest PharmaTech Inc.
Website
https://questpharmatech.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Quest PharmaTech Inc. is a TSX-V listed Canadian clinical-stage pharmaceutical company developing the Mab AR 9.6 humanized monoclonal antibody targeting MUC16 for pancreatic and ovarian cancer therapy, imaging, and radioimmunotherapy applications, operating alongside equity stakes in Korean biotech OQPBIOM and OncoVent.
Ownership category
akta.pro rank

Quest PharmaTech industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Monoclonal antibody therapy
  • Cancer immunotherapy
  • Targeted oncology therapeutics
  • Radioimmunotherapy agents
  • Theranostic imaging

Where Quest PharmaTech is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Quest PharmaTech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Marketing channels2 records

Quest PharmaTech product offering

Product offering

Core offering

Quest PharmaTech is a Canadian pharmaceutical company developing antibody-based immunotherapeutic products for cancer centered on its lead candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated O-glycan on MUC16. The product pipeline includes targeted therapy for pancreatic and ovarian cancers, a near-infrared fluorescence antibody conjugate for fluorescence-guided surgery, a radio-labeled immunoPET imaging agent, and a radioimmunotherapy approach for MUC16-expressing tumors.

Product overview

Quest PharmaTech is a Canadian pharmaceutical company developing a portfolio of cancer therapeutics and diagnostics centered around its lead product candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated MUC16. The company's product pipeline includes therapeutic applications for pancreatic cancer, fluorescence-guided surgical imaging agents, immunoPET imaging agents, and radioimmunotherapy. The company also maintains strategic investments in biotechnology companies including OQPBIOM (26.6% ownership, Korean immunotherapy developer) and OncoVent (10.67% direct + 12% indirect ownership).

Differentiator

Problem solved

Functional benefit

Products and services

  • Mab AR 9.6 A humanized monoclonal antibody targeting truncated O-glycan on MUC16 for targeted cancer therapy applications, including pancreatic cancer and ovarian cancer treatment. The antibody blocks oncogenic activities and tumor growth by interfering with EGF receptor and alpha-4-beta-integrin signaling pathways. Intended for biopharmaceutical licensing partners and ultimately for oncology patients with MUC16-expressing tumors.
  • Fluorescence Antibody Conjugate for Intraoperative Imaging A near-infrared fluorescent antibody conjugate derived from Mab AR 9.6 for fluorescence-guided intraoperative imaging of pancreatic cancer. Enables surgeons to visualize MUC16-expressing tumor tissue during surgery, targeting improved surgical outcomes for oncology patients.
  • ImmunoPET Imaging Agent A radio-labeled immunoPET imaging agent based on Mab AR 9.6 for non-invasive imaging of ovarian and pancreatic cancer. Provides diagnostic imaging capability using a MUC16-targeted tracer for oncology clinicians and imaging centers.
  • Radioimmunotherapy (Mab AR 9.6-based) A radioimmunotherapy product candidate using Mab AR 9.6 for the treatment of cancers expressing MUC16, intended as a therapeutic option for patients with MUC16-positive tumors. Developed for oncology biopharmaceutical licensing partners and ultimately oncology patients.

Quantifiable outcome

  • Structural characterization of Mab AR 9.6 in complex with MUC16 revealed non-linear epitope influenced by glycosylation
  • +1 more outcomes

Companies that use Quest PharmaTech

Customer profile

Segments2 records

Ideal customer profiles2 records

Quest PharmaTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Quest PharmaTech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • AdBioTechminorOthers · 10 June 2025AdBioTech is a South Korea-based company proposed to be acquired by OQPBIOM. Quest PharmaTech, as the largest shareholder of OQPBIOM, has publicly opposed this acquisition citing it is not in the best interest of OQM or its shareholders and is evaluating legal options.
  • OQPBIOM Inc.coreStrategic or Co-development PartnerQuest PharmaTech holds 26.6% equity interest in OQPBIOM Inc., a Korean private biotechnology company developing immunotherapy assets. OncoQuest transferred its immunotherapy assets to OQPBIOM through a series of transactions. Quest is the largest shareholder and has expressed opposition to OQPBIOM's proposed acquisition of AdBioTech.
  • OncoVentcoreStrategic or Co-development PartnerQuest holds 10.67% direct ownership interest in OncoVent plus 12% indirect interest through its ownership in OncoQuest. OncoQuest owns 29% of OncoVent. OncoVent is linked as a partner company on Quest's website.
  • OncoQuestcoreStrategic or Co-development PartnerOncoQuest transferred immunotherapy assets to OQPBIOM. Quest maintains an ownership position in OncoQuest as part of its investment structure. OncoQuest Pharma USA Inc. is a Delaware-incorporated subsidiary.
  • CanariabiominorOthersCanariabio is listed as a linked partner company on Quest PharmaTech's website. Nature of relationship is not explicitly detailed.
  • OncoQuest Pharma USA Inc.coreOthersDelaware-incorporated company and subsidiary of OncoQuest. Filed Form D notice for $360,000 USD exempt securities offering in the United States.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Quest PharmaTech competitors and assessment

Company assessment

Direct peers

  • ImmunoGen (AbbVie): Antibody-drug conjugate developer focused on oncology, including ovarian cancer. Directly comparable to Quest in developing antibody-based targeted cancer therapeutics leveraging tumor antigens.
  • Medicenna Therapeutics: Canadian clinical-stage immunotherapy company developing antibody-based oncology therapeutics. Closely comparable as a small Canadian biotech pursuing novel cancer biologics with similar scale and stage.
  • MacroGenics: Clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. Directly comparable in focusing on engineered monoclonal antibodies and antibody-drug conjugates for oncology indications.
  • BriaCell Therapeutics: Canadian clinical-stage biotech developing immunotherapy for cancer (notably breast cancer). Comparable as a small Canadian oncology immunotherapy developer with similar development-stage positioning.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical leader in antibody-drug conjugates (DXd platform). Comparable as a developer of antibody-conjugate oncology therapeutics, though operating at vastly greater scale and breadth.
  • AstraZeneca: Global pharmaceutical company with significant ovarian cancer franchise (including anti-MUC16 initiatives). Comparable as a developer of MUC16-targeted and ovarian cancer therapies, though at vastly greater scale.
  • Seagen (Pfizer): Established oncology antibody-conjugate company (now part of Pfizer). Comparable as a developer of antibody-based targeted cancer therapeutics and antibody-drug conjugates, though at much greater scale.

Regional players

  • Helix BioPharma: Canadian clinical-stage biopharmaceutical company developing immunotherapies for cancer. Comparable as a small Canadian oncology biotech with similar jurisdictional and capital-market profile.
  • Oncolytics Biotech: Canadian clinical-stage biotech developing immuno-oncology therapeutics (pelareorep). Comparable as a small Canadian oncology immunotherapy developer with similar jurisdictional profile.

Emerging players

  • CytomX Therapeutics: Clinical-stage oncology developer using Probody platform to engineer antibody-based therapeutics with tumor-selective activity. Comparable in developing engineered monoclonal antibody approaches for cancer therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Quest PharmaTech social profiles

Digital presence

Quest PharmaTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quest PharmaTech leadership team

Management profile

Number of profiles

Profiles5 records

Quest PharmaTech subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Quest PharmaTech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quest PharmaTech M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quest PharmaTech

What does Quest PharmaTech do?

Quest PharmaTech is a Canadian pharmaceutical company developing antibody-based immunotherapeutic products for cancer centered on its lead candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated O-glycan on MUC16. The product pipeline includes targeted therapy for pancreatic and ovarian cancers, a near-infrared fluorescence antibody conjugate for fluorescence-guided surgery, a radio-labeled immunoPET imaging agent, and a radioimmunotherapy approach for MUC16-expressing tumors.

Is Quest PharmaTech a public or private company?

Quest PharmaTech is a public company. It is classified as public and is currently operating.

When was Quest PharmaTech founded?

Quest PharmaTech was founded in 2006. It employs 1 to 10 people.

Where is Quest PharmaTech based?

Quest PharmaTech is headquartered in Edmonton, Canada, in the North America region.

Who are Quest PharmaTech's main competitors?

Direct peers on record are ImmunoGen (AbbVie), Medicenna Therapeutics, MacroGenics and BriaCell Therapeutics. Broad incumbents are Daiichi Sankyo, AstraZeneca and Seagen (Pfizer). Regional players are Helix BioPharma and Oncolytics Biotech. CytomX Therapeutics is listed as an emerging player.

Does Quest PharmaTech have an API?

No public API is recorded for Quest PharmaTech.

What industry is Quest PharmaTech in?

Quest PharmaTech's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceQuest PharmaTech Announces Change of Chief Executive OfficerQuest PharmaTech announced that Dr. Madi Madiyalakan will retire as CEO on November 23, 2026, and director Jeffrey Shon will succeed him. The company will hold its annual general meeting on that date, and Dr. Madiyalakan will continue consulting.GlobeNewswireQuest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual BasisQuest PharmaTech Inc., a CanadianTSX-V listed pharmaceutical company, filed its annual audited financial statements for the year ended January 31, 2026, on SEDAR+, reporting net income of $5.0 million, total assets of $27.8 million, and a 26.6% equity interest in a Korean private company OQPBIOM valued at $19.8 million. The company also announced its voluntary adoption of CSA Coordinated Blanket Order 51-933, which allows qualifying venture issuers to file financial statements and MD&A on a semi-annual rather than quarterly basis, thereby relieving the company from the administrative burden of first and third quarter filings. CEO Dr. Madi Madiyalakan stated the change will allow the company to focus its efforts on creating shareholder value.GlobeNewswireQuest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTechQuest PharmaTech announced it opposes OQPBIOM's acquisition of a controlling interest in AdBioTech, a vehicle for advancing oregovomab's clinical trials. Quest, OQPBIOM's largest shareholder with a 26.25% stake, was not informed or consulted and is consulting advisors on legal options.GlobeNewswireQuest PharmaTech Provides Corporate UpdateQuest PharmaTech filed its annual audited financials for the year ended January 31, 2025, reporting a net loss of $1.8 million and total assets of $22.6 million. The company converted all its OQP Bio bonds into shares of OQPBIOM Inc., now holding 26.25% of the Korean immunotherapy firm. It plans to engage an independent valuator for future financial statements.NewswireQuest PharmaTech Provides Corporate UpdateQuest PharmaTech said OQP Bio's parent, Canaria Bio, breached an agreement in principle for monetizing Quest's bonds, and parties are negotiating a buyer. OncoQuest, a 42.5% owned investee, filed Korean proceedings seeking about $14.5 million unpaid from the 2020 asset sale.PR NewswireQuest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical OncologistsQuest PharmaTech announced that clinical investigators associated with OncoQuest Pharmaceuticals will present data on the drug oregovomab at the 2021 American Society of Clinical Oncology conference. The presentations cover progress from the ongoing FLORA 5 phase III trial and final results from a Phase 1b study involving recurrent ovarian cancer patients. Quest also disclosed its annual shareholder meeting details, filed financial statements, and granted stock options to officers.NewswireUPDATE - IIROC Trading Halt - QPTIIROC halted trading in Quest PharmaTech Inc. (QPT) on May 4, 2020, at 10:07 a.m. ET, citing pending clarification of company affairs. The halt is a temporary suspension to ensure a fair and orderly market.PR NewswireQuest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.Quest PharmaTech Inc. has entered into a license agreement with OncoCare Therapeutics to develop and commercialize its Targeted Cancer Therapy Technology in the United States. In exchange for U.S. rights, Quest will receive a 45% ownership stake in OncoCare Therapeutics, which will lead the development of candidates AR 9.6 and ACP-2127 for pancreatic cancer treatment.PR NewswireOncoQuest to Present at BIO CEO & Investor ConferenceOncoQuest Inc., a biopharmaceutical company focused on cancer immunotherapy, announced it will present at the BIO CEO & Investor Conference on February 12, 2018, in New York City, with CFO Hany Awadalla providing a business overview and meeting with investors. The company's lead product oregovomab, an immunotherapy candidate for ovarian cancer, is currently undergoing multiple Phase 2 clinical trials. OncoQuest operates as a subsidiary of Quest PharmaTech Inc. and has a joint venture with OncoVent Co. Ltd. for the development of its MUC1 program in Greater China.PR NewswireMadenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin™ Serum for Anti-AgingMadenco Biosciences Inc., a subsidiary of Quest PharmaTech Inc., announced the creation of the SP-DERM line of cosmeceuticals targeting dermatologists and medi-spas, comprising three products: SP-DERM Recovery (post-procedural cream), SP-DERM Maintenance (maintenance cream), and SP-DERM Acne (scar serum), based on their proprietary SP-Technology platform. A preliminary pilot study demonstrated improvement in acne scar appearance after 4 and 8 weeks of treatment with SP-DERM Acne, with further controlled clinical studies warranted. The company also disclosed existing sale agreements for Bellus Skin Serum in the European Union with Swiss-based HCBD AG and in ASEAN countries with Singapore-based Merhati-Innokeys, with first shipments to Singapore imminent.